The biotechnology market is entering a new growth phase, driven by the convergence of genomic science, artificial intelligence, and precision medicine.

Federal regulators are trying to make it easier to develop cheaper alternatives to powerful drugs that many Americans depend ...

The U.S. Food and Drug Administration is preparing to accelerate approvals for biosimilars, or generic versions of complex ...